Transcriptional Dysregulation of MYC Reveals Common Enhancer-Docking Mechanism

Cell Rep. 2018 Apr 10;23(2):349-360. doi: 10.1016/j.celrep.2018.03.056.

Abstract

Transcriptional dysregulation of the MYC oncogene is among the most frequent events in aggressive tumor cells, and this is generally accomplished by acquisition of a super-enhancer somewhere within the 2.8 Mb TAD where MYC resides. We find that these diverse cancer-specific super-enhancers, differing in size and location, interact with the MYC gene through a common and conserved CTCF binding site located 2 kb upstream of the MYC promoter. Genetic perturbation of this enhancer-docking site in tumor cells reduces CTCF binding, super-enhancer interaction, MYC gene expression, and cell proliferation. CTCF binding is highly sensitive to DNA methylation, and this enhancer-docking site, which is hypomethylated in diverse cancers, can be inactivated through epigenetic editing with dCas9-DNMT. Similar enhancer-docking sites occur at other genes, including genes with prominent roles in multiple cancers, suggesting a mechanism by which tumor cell oncogenes can generally hijack enhancers. These results provide insights into mechanisms that allow a single target gene to be regulated by diverse enhancer elements in different cell types.

Keywords: chromosome structure; enhancer docking; gene regulation; super-enhancers.

MeSH terms

  • Amino Acid Motifs
  • Binding Sites
  • CCCTC-Binding Factor / metabolism
  • CRISPR-Cas Systems / genetics
  • Cell Line, Tumor
  • Cell Proliferation
  • DNA Methylation
  • Enhancer Elements, Genetic*
  • Gene Editing
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Promoter Regions, Genetic
  • Protein Binding
  • Proto-Oncogene Proteins c-myc / genetics
  • Proto-Oncogene Proteins c-myc / metabolism*

Substances

  • CCCTC-Binding Factor
  • Proto-Oncogene Proteins c-myc